Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. METHODS: In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes. RESULTS: Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups. CONCLUSIONS: In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but subgroup analyses suggested a benefit of oral insulin in individuals with the highest titres of insulin auto-antibodies.142,143”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“The Diabetes Prevention Trial—Type 1, tested whether oral or parental insulin prevented the development of type 1 diabetes in people who were autoantibody positive. Neither approach reduced diabetes development,”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“If one islet autoantibody is found, the test should be repeated and the other autoantibodies should be assayed because the risk of type 1 diabetes increases if two or more autoantibodies are positive (443).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [443]
In the citing paper
“Subcutaneously or intranasally delivered insulin was found to have no preventive effects.39,48”
From The future of type 1 diabetes therapy (2025) · cites this paper as [48]
In the citing paper
“Risk can be assessed by islet cell autoantibodies alone, without the need for evaluating endogenous insulin reserves, as was done for the U.S. DPT-1 trial (306).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [306]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
Epstein, F. H., Atkinson, M. A., & Maclaren, N. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312107 · Cited by 1,078
Verge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Cognitive Deficits in Adolescents Who Developed Diabetes Early in Life
Ryan, C., Vega, A., & Drash, A. (1985) · Pediatrics · doi:10.1542/peds.75.5.921 · Cited by 413
Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy
Atkinson, M. A., Maclaren, N. K., & Luchetta, R. (1990) · Diabetes · doi:10.2337/diab.39.8.933 · Cited by 299
Insulin prophylaxis in individuals at high risk of type 1 diabetes
Keller, R. J., Jackson, R. A., Eisenbarth, G. S., & Eisenbarth, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91215-8 · Cited by 298
Pugliese, A., Gianani, R., Moromisato, R., Awdeh, Z. L., Alper, C. A., Erlich, H. A., Jackson, R. A., & Eisenbarth, G. S. (1995) · Diabetes · doi:10.2337/diab.44.6.608 · Cited by 207
Gotfredsen, C. F., Buschard, K., & Frandsen, E. K. (1985) · Diabetologia · doi:10.1007/bf00703140 · Cited by 205
Vardi, P., Dib, S. A., Tuttleman, M., Connelly, J. E., Grinbergs, M., Radizabeh, A., Riley, W. J., Maclaren, N. K., Eisenbarth, G. S., & Soeldner, J. S. (1987) · Diabetes · doi:10.2337/diab.36.11.1286 · Cited by 192
Attentional Functioning in Children and Adolescents With IDDM
Rovet, J., & Alvarez, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.803 · Cited by 153
Cited by
Items 401–500 of 832
Dib, S. A., & Gomes, M. B. (2009) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-1-25 · Cited by 27
Staging the progression to type 1 diabetes with prediagnostic markers
Sosenko, J. M. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000267 · Cited by 25
Acute Metabolic Complications in Diabetes
Rewers, A. (2018) · Europe PMC (PubMed Central) · Cited by 37
Pathophysiologic, Diagnostic, and Therapeutic Aspects of the Metabolic Syndrome
Giles, T. D., & Sander, G. E. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04763.x · Cited by 29
Hansenne, I. (2005) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2005.01301.x · Cited by 20
Sosenko, J. M., Skyler, J. S., Beam, C. A., Boulware, D. C., Mahon, J. L., Krischer, J. P., Greenbaum, C. J., Rafkin, L. E., Matheson, D., Herold, K. C., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2787 · Cited by 19
Achieving Antigen-Specific Tolerance in Diabetes: Regulating Specifically
Chen, W., Bluestone, J. A., & Herold, K. C. (2005) · International Reviews of Immunology · doi:10.1080/08830180500379671 · Cited by 22
Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials
Thomas, H. R., & Gitelman, S. E. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12040 · Cited by 19
Vaccination against type 1 diabetes
Larsson, H. E., & Lernmark, Å. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02386.x · Cited by 19
Misso, M. L., Egberts, K. J., Page, M. J., O’Connor, D. A., & Shaw, J. E. (2010) · Evidence-Based Child Health A Cochrane Review Journal · doi:10.1002/ebch.623 · Cited by 18
Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Mittermayer, F., Caveney, E. J., OLIVEIRA, C. D. F., Fleming, G. A., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160413115655 · Cited by 20
Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities
Beik, P., Ciesielska, M., Kucza, M., Kurczewska, A., Kuźmińska, J., Maćkowiak, B., & Niechciał, E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092805 · Cited by 18
Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes
Johnson, M. C., Wang, B., & Tisch, R. (2011) · Human Vaccines · doi:10.4161/hv.7.1.12848 · Cited by 19
Ma, X., Becker, D. J., Arena, V. C., Vicini, P., & Greenbaum, C. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2687 · Cited by 18
Higashide, T., Kawamura, T., Nagata, M., Kotani, R., Kimura, K., Hirose, M., Inada, H., Niihira, S., & Yamano, T. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000200803.72985.3c · Cited by 18
Prevention strategies for type 1 diabetes: a story of promising efforts and unmet expectations
Kanta, A., Lyka, E., Koufakis, T., Zebekakis, P. E., & Kotsa, K. (2020) · HORMONES · doi:10.1007/s42000-020-00207-9 · Cited by 18
Immunotherapies for prevention and treatment of type 1 diabetes
Jeun, R. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2473311 · Cited by 21
Learning From Past Failures of Oral Insulin Trials
Michels, A. W., & Gottlieb, P. A. (2018) · Diabetes · doi:10.2337/dbi17-0043 · Cited by 17
A century later, still fighting back: antigen‐specific immunotherapies for type 1 diabetes
Rodríguez-Fernández, S., Almenara‐Fuentes, L., Perna‐Barrull, D., Barneda‐Zahonero, B., & Vives‐Pi, M. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12439 · Cited by 18
Trials in the Prevention of Type 1 Diabetes: Current and Future
Wherrett, D. K. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.004 · Cited by 19
Molecular Interactions Governing Autoantigen Presentation in Type 1 Diabetes
Nakayama, M., Simmons, K. M., & Michels, A. W. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0689-z · Cited by 18
Sbierski‐Kind, J., Kath, J., Brachs, S., Streitz, M., von Herrath, M. G., Kühl, A. A., Schmidt‐Bleek, K., Mai, K., Spranger, J., & Volk, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01069 · Cited by 23
Type 1 diabetes mellitus: primary, secondary, and tertiary prevention
Bollyky, J., Sanda, S., & Greenbaum, C. J. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20054 · Cited by 18
Evans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetes Care · doi:10.2337/dci25-0013 · Cited by 24
Mahon, J. L., Beam, C. A., Marcovina, S. M., Boulware, D. C., Palmer, J. P., Winter, W. E., Skyler, J. S., & Krischer, J. P. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.07.019 · Cited by 17
Lessons from Type 1 Diabetes for Understanding Natural History and Prevention of Autoimmune Disease
Simmons, K. M., & Michels, A. W. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.07.008 · Cited by 20
Fändrich, F., & Ungefroren, H. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_28 · Cited by 19
Lin, Y., Qian, X., Krischer, J. P., Vehik, K., Lee, H., & Huang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091095 · Cited by 21
DiaPep277® and immune intervention for treatment of type 1 diabetes
Schloot, N. C., & Cohen, I. R. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.001 · Cited by 18
TH1/TH2 cytokine secretion of first degree relatives of T1DM patients
Rapoport, M. J., Bistritzer, T., Aharoni, D., Weiss, M., Ramot, Y., Buchs, A. E., Bloch, K., & Vardi, P. (2005) · Cytokine · doi:10.1016/j.cyto.2005.01.012 · Cited by 20
Prediabetes in Children: Natural History, Diagnosis, and Preventive Strategies
Kulmala, P. (2003) · Pediatric Drugs · doi:10.2165/00128072-200305040-00001 · Cited by 20
Åkesson, L., Trygg, J., Fuller, J. M., Madsen, R., Gabrielsson, J., Bruce, S., Stenlund, H. C., Tupling, T., Pefley, R., Lundstedt, T., et al. (2011) · Metabolomics · doi:10.1007/s11306-011-0278-3 · Cited by 15
Current and future efforts toward the prevention of type 1 diabetes
Jacobsen, L. M., & Schatz, D. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12333 · Cited by 17
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes
Lord, S. M., & Greenbaum, C. J. (2020) · F1000Research · doi:10.12688/f1000research.21801.1 · Cited by 15
Harnessing CD8+ T‐cell exhaustion to treat type 1 diabetes
Kwong, C.-T. J., Selck, C., Tahija, K., McAnaney, L. J., Le, D. V., Kay, T. W. H., Thomas, H. E., & Krishnamurthy, B. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12444 · Cited by 17
Noce, M. L., Nicoletti, G. F., Papaccio, G., Vecchio, V. D., & Papaccio, F. (2022) · Cells · doi:10.3390/cells11233941 · Cited by 16
Short‐term subcutaneous insulin treatment delays but does not prevent diabetes in NOD mice
Brezar, V., Čulina, S., Gagnerault, M. C., & Mallone, R. (2012) · European Journal of Immunology · doi:10.1002/eji.201242394 · Cited by 15
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
Lord, S. M., & Greenbaum, C. J. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.02.002 · Cited by 16
Scridon, A., Perian, M., Mărginean, A., Fiscă, C., Vântu, A., Gherțescu, D., Chevalier, P., & Şerban, R. C. (2015) · Revista română de medicină de laborator · doi:10.1515/rrlm-2015-0028 · Cited by 20
Prevention or Early Cure of Type 1 Diabetes by Intranasal Administration of Gliadin in NOD Mice
Funda, D. P., Fundová, P., Hansen, A. K., & Buschard, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094530 · Cited by 17
Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword
Pugliese, A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18395 · Cited by 15
von Boehmer, H. (2005) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2005.01609.x · Cited by 16
Therapy to Prevent Type 1 Diabetes Mellitus
Carel, J., Landais, P., & Bougneres, P. F. (2002) · New England Journal of Medicine · doi:10.1056/nejm200210033471415 · Cited by 15
Self-Antigens Targeted by Regulatory T Cells in Type 1 Diabetes
Mitchell, A. M., & Michels, A. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063155 · Cited by 19
Harley, I. T. W., Allison, K., & Scofield, R. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953439 · Cited by 15
Immunotherapies in Diabetes Mellitus Type 1
Gupta, S. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.008 · Cited by 15
A Screening System for Detecting Genetic Risk Markers of Type 1 Diabetes in Dried Blood Spots
Dantonio, P., Meredith, N. K., Earley, M. C., Cordovado, S. K., Callan, W. J., Rollin, D., Morris, D., Vogt, R. F., & Hannon, W. H. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.433 · Cited by 14
A future for CD3 antibodies in immunotherapy of type 1 diabetes
Chatenoud, L. (2019) · Diabetologia · doi:10.1007/s00125-018-4808-7 · Cited by 18
Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes
Nakayama, M., & Michels, A. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00365 · Cited by 17
Sperling, M. A., Tamborlane, W. V., Battelino, T., WEINZIMER, S. A., & Phillip, M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00028-7 · Cited by 16
Latent autoimmune diabetes of adulthood
Nabhan, F. A., Emanuele, M. A., & Emanuele, N. (2005) · Postgraduate Medicine · doi:10.3810/pgm.2005.03.1597 · Cited by 15
Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes
Azam, A., & Eisenbarth, G. S. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.10.1569 · Cited by 16
Type 1 diabetes: immune pathology and novel therapeutic approaches
Ling, E. M., Lemos, J. R. N., Hirani, K., & von Herrath, M. (2024) · Diabetology International · doi:10.1007/s13340-024-00748-z · Cited by 14
Felton, J. L., Conway, H., & Bonami, R. H. (2021) · Biomedicines · doi:10.3390/biomedicines9010042 · Cited by 13
SerpinB13 antibodies promote β cell development and resistance to type 1 diabetes
Kryvalap, Y., Jiang, M., Kryvalap, N., Hendrickson, C., & Czyzyk, J. K. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1587 · Cited by 14
Balti, E. V., Vandemeulebroucke, E., Weets, I., de Velde, U. V., Dalem, A. V., Demeester, S., Verhaeghen, K., Gillard, P., Block, C. E. M. D., Ruige, J. B., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2035 · Cited by 14
Geenen, V., Louis, C., & Martens, H. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1337.008 · Cited by 13
Treg Vaccination in Autoimmune Type 1 Diabetes
Serr, I., Weigmann, B., Franke, R. K., & Daniel, C. (2013) · BioDrugs · doi:10.1007/s40259-013-0060-3 · Cited by 15
Ryhänen, S. J., Härkönen, T., Siljander, H., Näntö‐Salonen, K., Simell, T. T., Hyöty, H., Ilonen, J., Veijola, R., Simell, O., & Knip, M. (2011) · Diabetes Care · doi:10.2337/dc10-1449 · Cited by 13
Antigen-based vs. systemic immunomodulation in type 1 diabetes: The pros and cons
Robert, S., Korf, H., Gysemans, C. A., & Mathieu, C. (2013) · Islets · doi:10.4161/isl.24785 · Cited by 16
β cell responses to inflammation
Usmani‐Brown, S., Perdigoto, A. L., Lavoie, N., Clark, P. L., Korah, M. M., Rui, J., Betancur, G., & Herold, K. C. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.013 · Cited by 14
Casu, A., Trucco, M., & Pietropaolo, M. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.07.002 · Cited by 14
From pumps to prevention: recent advances in the treatment of type 1 diabetes
Sherr, J. L., Cengiz, E., & Tamborlane, W. V. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.011 · Cited by 16
Diabetic ketoacidosis in children: the problems continue
Sperling, M. A. (2005) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2005.00111.x · Cited by 13
Voss, M. G., Cuthbertson, D. D., Cleves, M., Xu, P., Evans‐Molina, C., Palmer, J. P., REDONDO, M. J., Steck, A. K., Lundgren, M., Larsson, H. E., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0226 · Cited by 13
Melin, J., Lynch, K. F., Lundgren, M., Aronsson, C. A., Larsson, H. E., Johnson, S. B., TEDDY Study Group, Rewers, M., Barbour, A., BAUTISTA, K. A., et al. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00929-w · Cited by 12
Current Controversies in Treatment and Prevention of Diabetic Ketoacidosis
Rewers, A. (2010) · Advances in Pediatrics · doi:10.1016/j.yapd.2010.09.001 · Cited by 12
Sosenko, J. M., Mahon, J. L., Rafkin, L. E., Lachin, J. M., Krause-Steinrauf, H. J., Krischer, J. P., Cuthbertson, D. D., Palmer, J. P., Thompson, C. M., Greenbaum, C. J., et al. (2010) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2010.00662.x · Cited by 12
Type 1 diabetes: focus on prevention
von Boehmer, H. (2004) · Nature Medicine · doi:10.1038/nm0804-783 · Cited by 12
Marée, A. F. M., Santamaria, P., & Edelstein-Keshet, L. (2006) · International Immunology · doi:10.1093/intimm/dxl040 · Cited by 12
Ludwig, B., Barthel, A., Reichel, A., Block, N. L., Ludwig, S., Schally, A. V., & Bornstein, S. R. (2014) · Vitamins and hormones · doi:10.1016/b978-0-12-800174-5.00008-9 · Cited by 13
Metabolic tests to determine risk for type 1 diabetes in clinical trials
Greenbaum, C. J., Buckingham, B., Chase, H. P., Krischer, J., & for the Diabetes Prevention Trial, T. 1. D. (. S. G. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1205 · Cited by 12
Strategies to prevent type 1 diabetes
Thrower, S., & Bingley, P. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01064.x · Cited by 13
Andrén‐Sandberg, Å., & Hardt, P. D. (2005) · PubMed · Cited by 18
The Immunoendocrinopathy Syndromes
Barker, J. M., Gottlieb, P. A., & Eisenbarth, G. S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00042-0 · Cited by 13
Innovative Immune-Based Therapeutic Approaches for the Treatment of Type 1 Diabetes Mellitus
Eldor, R., Cohen, I. R., & Raz, I. (2005) · International Reviews of Immunology · doi:10.1080/08830180500379697 · Cited by 12
Greenbaum, C. J., Eisenbarth, G. S., Atkinson, M. A., Yu, L., Babu, S. R., Schatz, D., Zeidler, A., Orban, T., Wasserfall, C. H., Cuthbertson, D. D., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1608-z · Cited by 15
Self-citationAntigen-specific T cell responses in autoimmune diabetes
Dwyer, A. J., Shaheen, Z. R., & Fife, B. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440045 · Cited by 17
Particle-Based therapies for antigen specific treatment of type 1 diabetes
Lukesh, N. R., Middleton, D. D., Bachelder, E. M., & Ainslie, K. M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122500 · Cited by 12
Zhao, L. P., Papadopoulos, G. K., Skyler, J. S., Pugliese, A., Parikh, H. M., Kwok, W. W., Lybrand, T. P., Bondinas, G. P., Moustakas, A. K., Wang, R., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1947 · Cited by 13
The Imperative to Prevent Diabetes
Ratner, R. E. (2012) · Diabetes Care · doi:10.2337/dc12-1997 · Cited by 14
Linking autoantigen properties to mechanisms of immunity
Griffin, J. D., Song, J. Y., Sestak, J. O., DeKosky, B. J., & Berkland, C. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.005 · Cited by 12
Insulin immunotherapy for pretype 1 diabetes
Jacobsen, L. M., & Schatz, D. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000648 · Cited by 11
Aggarwal, A., Rawn, J. D., Pendergrass, M., & Garg, R. (2011) · Endocrine Practice · doi:10.4158/ep10354.or · Cited by 11
Etiopathogenesis of Insulin Autoimmunity
Kanatsuna, N., Papadopoulos, G. K., Moustakas, A. K., & Lernmark, Å. (2012) · Anatomy Research International · doi:10.1155/2012/457546 · Cited by 14
Prevention strategies for type 1 diabetes
Kishiyama, C. M., Chase, H. P., & Barker, J. M. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9015-z · Cited by 11
MCS-18, a novel natural plant product prevents autoimmune diabetes
Seifarth, C., Littmann, L., Resheq, Y. J., Rößner, S., Goldwich, A., Pangratz, N., Kerek, F., Steinkasserer, A., & Zinser, E. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.04.016 · Cited by 12
Type 1 Diabetes in the Child and Adolescent
Haller, M. J., Silverstein, J. H., & Rosenbloom, A. L. (2006) · CRC Press eBooks · doi:10.3109/9781439808948-5 · Cited by 11
Coping with Diabetes: Psychological Determinants of Diabetes Outcomes
Wagner, J. A., & Tennen, H. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-48670-3_11 · Cited by 13
Drug Insight: new immunomodulatory therapies in type 1 diabetes
Cernea, S., & Herold, K. C. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0082 · Cited by 13
Islet replacement vs. regeneration: Hope or hype?
Ramiya, V. K., & Schatz, D. (2004) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2004.00079.x · Cited by 15
Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright Future
Mallone, R., Sims, E. K., Achenbach, P., Mathieu, C., Pugliese, A., Atkinson, M. A., Dutta, S., Evans‐Molina, C., Klatzmann, D., Koralova, A., et al. (2024) · Diabetes · doi:10.2337/db24-0439 · Cited by 11
Baidal, D. A., WARNOCK, M. V., Xu, P., Geyer, S. M., Marks, J. B., Moran, A., Sosenko, J. M., & Evans‐Molina, C. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac285 · Cited by 10
Zhao, L. P., Skyler, J. S., Papadopoulos, G. K., Pugliese, A., Najera, J. A., Bondinas, G. P., Moustakas, A. K., Wang, R., Pyo, C., Nelson, W. C., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1628 · Cited by 11
Rai, U., Senapati, D., & Arora, M. K. (2022) · Diabetology International · doi:10.1007/s13340-022-00607-9 · Cited by 10
Wherrett, D. K., & Daneman, D. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.07.010 · Cited by 11
Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice
Grönholm, J., Pagni, P. P., Pham, M. N., Gibson, C. B., Macomber, P. F., Vela, J. L., von Herrath, M., & Lenardo, M. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4276-5 · Cited by 10
Current aspects on the clinical immunology and genetics of autoimmune diabetes in Japan
Kawasaki, E., & Eguchi, K. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.042 · Cited by 10
Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes
Belgian Diabetes Registry, Truyen, I., Grijse, J. D., Weets, I., Kaufman, L., Pipeleers, L., Nanos, N., Decochez, K., Hilbrands, R., Kaufman, J.-M., et al. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03416.x · Cited by 10
Immune therapy in type 1 diabetes mellitus — Attempts to untie the Gordian knot?
Perakakis, N., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.016 · Cited by 10
Metadata
- Authors
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Affiliations
- University of Miami (US)
- Corresponding author
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-30
- Volume
- 346
- Issue
- 22
- Pages
- 1685-1691
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W614574849
- Cited by
- 836
- References
- 30
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 27 · 2016: 26 · 2015: 34 · 2014: 30 · 2013: 38 · 2012: 42
- FWCI
- 28.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, insulin therapy, diabetes prevention, relatives of diabetic patients, islet cell antibodies, ultralente insulin, continuous intravenous insulin infusion, glucose tolerance, hypoglycemia, disease progression
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Glucose Tolerance Test, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Islets of Langerhans, Male, Middle Aged, Risk Factors, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.